Combining excellent clinical understanding and patient centric programs with cutting-edge technologies for the development of new treatments for Parkinson disease and related disorders.
about us
"Empowering lives through innovative neuroscience solutions, Agyany is dedicated to redefining Parkinson's disease treatment and delivering hope to patients worldwide."
Parkinson’s Disease affects over 10 million people worldwide—with no cure and limited treatment options that only manage symptoms. Among them, nearly 1 million suffer from GBA1-associated Parkinson’s (Sidransky Syndrome)—a faster-progressing, genetically defined form with even greater unmet needs.
Our Breakthrough Solution: Ambroxol
We are developing Ambroxol, an oral, repurposed therapy with disease-modifying potential for GBA1-associated Parkinson’s Disease (SidSyn). Originally an over-the-counter mucolytic agent, Ambroxol is now being positioned as the first treatment to target the genetic and molecular drivers of Parkinson’s, not just its symptoms.
Why Ambroxol?
• Targets the Root Cause – Corrects enzyme misfolding in the brain
• Crosses the Blood-Brain Barrier – Acts directly on affected neurons
• Improves Enzyme Function – Reduces toxic protein buildup
• Backed by Clinical Data – Currently in Phase I/II trials
innovation
Pioneering Breakthroughs in Parkinson's Disease Treatment through Scientific Innovation
"Joleen Istaiti is a remarkable example of a fine human being combined with an efficient and thoughtful member of the research community. She is a delightful person with whom to work and she will always bring something positive, forward-looking and new to the table. She is an asset to the research community and business and I am sure is to this company."
S.S , USA
"I'm very pleased with my response to ambroxol! My handwriting has improved, and my fingers are moving comfortably on my computer keyboard. I am very hopeful and extremely appreciative of Ari's efforts in the field of Parkinson's disease."
D.E , Israel
Ari Zimran and Arndt Rolfs are exceptional medical pioneers, known for their unwavering commitment to ethical care and their expertise in diagnostic and innovative laboratory methodologies. They have successfully opened doors for patients, embodying the best in the science and the art of medicine.
T.T , Georgia
"I've had the privilege of collaborating with Agyany's founders for years. Their expertise in rare disease diagnostics and biomarker discovery has earned the trust of thousands worldwide! The Agyany team are reliable, trustworthy partners, deeply passionate about enhancing the health and quality of life for rare disease and Parkinson's patients and their families."
pipeline
Our pipeline starts with strong science aimed at translating important and central mechanisms of PD development into new medicines. Agyany is developing first-in-class therapies for Parkinson’s disease, starting with a well-known and proven drug, ambroxol for patients having the GBA1 variant.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
